LeaningCausality

Is lipoprotein(a), or Lp(a), an independent causal risk factor for heart disease?

Lipoprotein(a) [Lp(a)] is an independent, largely genetically determined causal risk factor for atherosclerotic cardiovascular disease.

Lp(a) is a particle most people never get tested for, yet the genetic evidence that it causes heart disease is unusually strong - arguably cleaner than for LDL itself, because Lp(a) levels are set mostly by your genes from birth. This makes it a near-ideal natural experiment. The main open questions are not whether it is causal, but how much it adds on top of LDL and whether lowering it helps.

Limited evidence so far: This claim currently rests on only 2 assessments. It is early-corpus and should be read as provisional - see the methodology and coverage matrix for the planned additions.

Evidence balance

Supports: 2(100% weighted share)Challenges: 0(0% weighted share)

Segment widths are weighted by evidence strength (a meta-analysis counts for more than a case report), so they will not match the raw study counts shown above. This is deliberate: it stops a weak study from visually outweighing a strong one. The weighting is an editorial ordinal display scale, not a probability or a meta-analytic effect estimate. See the methodology for the tier weighting.

Mainstream steelman

Lp(a) is largely fixed by genetics, so genetic studies sidestep the confounding that plagues diet and lifestyle research. Mendelian randomization in large population cohorts links genetically elevated Lp(a) to higher myocardial infarction risk, and genetic variants that raise Lp(a) raise coronary disease risk in a dose-dependent way. Crucially, when the analysis is adjusted for the Lp(a) level itself, the genetic association with disease disappears - the signature of a genuine causal mediator rather than a marker. Multiple independent genetic designs converge on the same answer.

Skeptic steelman

Even granting causality, the practical questions are unsettled. Lp(a) explains a minority of cardiovascular events, its effect is smaller per particle than the attention it now receives might suggest, and until very recently there was no approved therapy that lowers it and reduces events - so a causal marker you cannot yet act on has limited clinical value. Some also argue Lp(a)'s risk overlaps with LDL and apoB, so its truly independent contribution is easy to overstate.

Bottom line

High confidence

The genetic evidence that Lp(a) is causally involved in atherosclerotic disease is strong and unusually clean, because Lp(a) is genetically fixed and several independent genetic designs agree. The honest caveats are about magnitude and actionability, not direction: how much independent risk it adds, and whether lowering it reduces events, are still being resolved by ongoing trials.

This is a clearly-labelled editorial judgment, not a fact. It is written to survive its own skeptic steelman above.

What would change this conclusion

A large outcomes trial showing that lowering Lp(a) (for example with the newer targeted therapies) does NOT reduce cardiovascular events would challenge the causal interpretation; or genetic evidence that the Lp(a)-disease association is fully explained by correlated LDL or apoB rather than Lp(a) itself.

The evidence (2)

Strongest evidence first. Each card traces to a study and a verbatim quote with a locator.

SupportsHigh tierCoronary event
Genetic variants associated with Lp(a) lipoprotein level and coronary disease
The New England Journal of Medicine, 2009 - Mendelian Randomization
An independent genetic line of evidence converging on the same conclusion as the Mendelian-randomization anchor. Two independent common variants at the LPA locus each raise coronary-disease risk, a genetic dose-response that points to Lp(a) itself rather than a confounded marker. It supports (rather than strongly supports) because the abstract here reports the variant-to-disease associations; the full causal-mediation step is an additional analysis in the paper.
“We identified a common variant (rs10455872) at the LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval [CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio of 1.92 (95% CI, 1.48 to 2.49).”
- Abstract, Results
Applicability: Large case-control genetic association (PROCARDIS) plus replication; European populations.
- Genetic association alone; the formal causal-mediation analysis is reported in the body of the paper.
Strongly supportsHigh tierCoronary event
Genetically elevated lipoprotein(a) and increased risk of myocardial infarction
JAMA, 2009 - Mendelian Randomization
This is the causal anchor for the claim. Because lipoprotein(a) is set almost entirely by genetics, a Mendelian-randomization design tying genetically elevated Lp(a) to a dose-dependent rise in myocardial infarction sidesteps the confounding and reverse causation that weaken observational lipid evidence. Genetically raised Lp(a) predicting MI is the signature of a causal exposure, not a passive marker, which is why this strongly supports the causal claim.
“Genetically elevated lipoprotein(a) was associated with an HR of 1.22 (95% CI, 1.09-1.37) per doubling of lipoprotein(a) level”
- Abstract, Results
Applicability: General-population cohorts (Copenhagen); causal inference from genetic variation in Lp(a).
- Per-doubling effect size is modest; the claim it supports is direction (causal), not large absolute risk.